ALK and non-small cell lung carcinoma: In particular, the identification of ALK, ROS1, RET, and NTRK1/2/3 gene rearrangements by the scientific community has given an enormous change in therapeutic perspective for patients suffering from NSCLC in the advanced stage of the disease [17].